bms-833923 and Skin-Neoplasms

bms-833923 has been researched along with Skin-Neoplasms* in 2 studies

Reviews

2 review(s) available for bms-833923 and Skin-Neoplasms

Article	Year
Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC. The British journal of dermatology, 2013, Volume: 169, Issue:1 Basal cell carcinoma (BCC) is the most common cancer in the U.K. and its incidence is increasing. Vismodegib, a hedgehog pathway inhibitor, has recently been licensed by the U.S. Food and Drug Administration for treatment of advanced BCC. Phase 2 trials have demonstrated efficacy in cases of locally advanced and metastatic BCC, as well as cases of hereditary basal cell naevus (Gorlin) syndrome. Side-effects are frequent and considerable and include myalgia, taste disturbance, alopecia, weight loss and fatigue. Further research is needed to investigate means of circumventing these side-effects, and longitudinal data are required to assess the long-term benefits of, and the nature of resistance to, this novel class of agents. Alternative hedgehog inhibitors are currently in clinical development. We review the current data pertaining to this novel treatment modality and discuss its likely future role in the management of BCC. Topics: Anilides; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Carcinoma, Basal Cell; Clinical Trials as Topic; Hedgehog Proteins; Humans; Pyridines; Quinazolines; Skin Neoplasms	2013
Emerging treatments and signaling pathway inhibitors. Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:4 Suppl A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway. Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Basal Cell Nevus Syndrome; Benzamides; Carcinoma, Basal Cell; Deoxyribonuclease (Pyrimidine Dimer); Fluorouracil; Hedgehog Proteins; Humans; Imiquimod; Photochemotherapy; Pyridines; Quinazolines; Retinoids; Secondary Prevention; Signal Transduction; Skin Neoplasms; Viral Proteins	2011

Article

Year

Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.

The British journal of dermatology, 2013, Volume: 169, Issue:1

Basal cell carcinoma (BCC) is the most common cancer in the U.K. and its incidence is increasing. Vismodegib, a hedgehog pathway inhibitor, has recently been licensed by the U.S. Food and Drug Administration for treatment of advanced BCC. Phase 2 trials have demonstrated efficacy in cases of locally advanced and metastatic BCC, as well as cases of hereditary basal cell naevus (Gorlin) syndrome. Side-effects are frequent and considerable and include myalgia, taste disturbance, alopecia, weight loss and fatigue. Further research is needed to investigate means of circumventing these side-effects, and longitudinal data are required to assess the long-term benefits of, and the nature of resistance to, this novel class of agents. Alternative hedgehog inhibitors are currently in clinical development. We review the current data pertaining to this novel treatment modality and discuss its likely future role in the management of BCC.

Topics: Anilides; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Carcinoma, Basal Cell; Clinical Trials as Topic; Hedgehog Proteins; Humans; Pyridines; Quinazolines; Skin Neoplasms

2013

Emerging treatments and signaling pathway inhibitors.

Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:4 Suppl

A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway.

Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Basal Cell Nevus Syndrome; Benzamides; Carcinoma, Basal Cell; Deoxyribonuclease (Pyrimidine Dimer); Fluorouracil; Hedgehog Proteins; Humans; Imiquimod; Photochemotherapy; Pyridines; Quinazolines; Retinoids; Secondary Prevention; Signal Transduction; Skin Neoplasms; Viral Proteins

2011